How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acyclovir-resistant-mucocutaneous-hsv-in-immunocompromised-patients.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vistide	CIDOFOVIR	Gilead Sciences	cidofovir		1996-01-01
Foscavir	FOSCARNET	Clinigen Hlthcare	Pyrophosphate Analog DNA Polymerase Inhibitor		1991-01-01
Vistide	Vistide	Gustave Roussy, Cancer Campus, Grand Paris		DNA polymerase catalytic subunit

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Clinigen Hlthcare · 1 drug in Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients
Gilead Sciences · 1 drug in Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients:

Cite this brief

Drug Landscape (2026). Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acyclovir-resistant-mucocutaneous-hsv-in-immunocompromised-patients. Accessed 2026-06-10.

Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing